This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/domain/vavai/projekt/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/resource/domain/vavai/subjekt/
n13http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n20http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00179906%3A_____%2F13%3A10193670%21RIV14-MZ0-00179906/
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00179906%3A_____%2F13%3A10193670%21RIV14-MZ0-00179906
rdf:type
n13:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1016/j.jcrc.2012.06.003
dcterms:description
Purpose: To determine bioenergetic gain of 2 different citrate anticoagulated continuous hemodiafiltration (CVVHDF) modalities and a heparin modality. Materials and Methods: We compared the bio-energetic gain of citrate, glucose and lactate between 29 patients receiving 2.2% acid-citrate-dextrose with calcium-containing lactate-buffered solutions (ACD/Ca-plus/lactate), 34 on 4% trisodium citrate with calcium-free low-bicarbonate buffered fluids (TSC/Ca-min/bicarbonate), and 18 on heparin with lactate buffering (Hep/lactate). Results: While delivered CVVHDF dose was about 2000 mL/h, total bioenergetic gain was 262kJ/h (IQR 230-284) with ACD/Ca-plus/lactate, 20 kJ/h (8-25) with TSC/Ca-min/bicarbonate (P < .01) and 60 kJ/h (52-76) with Hep/lactate. Median patient delivery of citrate was 31.2 mmol/h (25-34.7) in ACD/Ca-plus/lactate versus 14.8 mmol/h (12.4-19.1) in TSC/Ca-min/bicarbonate groups (P < .01). Median delivery of glucose was 36.8 mmol/h (29.9-43) in ACD/Ca-plus/lactate, and of lactate 52.5 mmol/h (49.259.1) in ACD/Ca-plus/lactate and 56.1 mmol/h (49.6-64.2) in Hep/lactate groups. The higher energy delivery with ACD/Ca-plus/lactate was partially due to the higher blood flow used in this modality and the calcium-containing dialysate. Conclusions: The bioenergetic gain of CVVHDF comes from glucose (in ACD), lactate and citrate. The amount substantially differs between modalities despite a similar CVVHDF dose and is unacceptably high when using ACD with calcium-containing lactate-buffered solutions and a higher blood flow. When calculating nutritional needs, we should account for the energy delivered by CVVHDF. Purpose: To determine bioenergetic gain of 2 different citrate anticoagulated continuous hemodiafiltration (CVVHDF) modalities and a heparin modality. Materials and Methods: We compared the bio-energetic gain of citrate, glucose and lactate between 29 patients receiving 2.2% acid-citrate-dextrose with calcium-containing lactate-buffered solutions (ACD/Ca-plus/lactate), 34 on 4% trisodium citrate with calcium-free low-bicarbonate buffered fluids (TSC/Ca-min/bicarbonate), and 18 on heparin with lactate buffering (Hep/lactate). Results: While delivered CVVHDF dose was about 2000 mL/h, total bioenergetic gain was 262kJ/h (IQR 230-284) with ACD/Ca-plus/lactate, 20 kJ/h (8-25) with TSC/Ca-min/bicarbonate (P < .01) and 60 kJ/h (52-76) with Hep/lactate. Median patient delivery of citrate was 31.2 mmol/h (25-34.7) in ACD/Ca-plus/lactate versus 14.8 mmol/h (12.4-19.1) in TSC/Ca-min/bicarbonate groups (P < .01). Median delivery of glucose was 36.8 mmol/h (29.9-43) in ACD/Ca-plus/lactate, and of lactate 52.5 mmol/h (49.259.1) in ACD/Ca-plus/lactate and 56.1 mmol/h (49.6-64.2) in Hep/lactate groups. The higher energy delivery with ACD/Ca-plus/lactate was partially due to the higher blood flow used in this modality and the calcium-containing dialysate. Conclusions: The bioenergetic gain of CVVHDF comes from glucose (in ACD), lactate and citrate. The amount substantially differs between modalities despite a similar CVVHDF dose and is unacceptably high when using ACD with calcium-containing lactate-buffered solutions and a higher blood flow. When calculating nutritional needs, we should account for the energy delivered by CVVHDF.
dcterms:title
Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration-a comparison between 2 citrate modalities and unfractionated heparin Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration-a comparison between 2 citrate modalities and unfractionated heparin
skos:prefLabel
Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration-a comparison between 2 citrate modalities and unfractionated heparin Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration-a comparison between 2 citrate modalities and unfractionated heparin
skos:notation
RIV/00179906:_____/13:10193670!RIV14-MZ0-00179906
n13:predkladatel
n14:ico%3A00179906
n3:aktivita
n16:P n16:I
n3:aktivity
I, P(NS10014)
n3:cisloPeriodika
1
n3:dodaniDat
n4:2014
n3:domaciTvurceVysledku
n6:9349162
n3:druhVysledku
n12:J
n3:duvernostUdaju
n11:S
n3:entitaPredkladatele
n20:predkladatel
n3:idSjednocenehoVysledku
63416
n3:idVysledku
RIV/00179906:_____/13:10193670
n3:jazykVysledku
n19:eng
n3:klicovaSlova
Renal replacement therapy; Hemodiafiltration; Citrate; Anticoagulation; Acute renal failure
n3:klicoveSlovo
n8:Acute%20renal%20failure n8:Hemodiafiltration n8:Citrate n8:Anticoagulation n8:Renal%20replacement%20therapy
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[76802ABF69EB]
n3:nazevZdroje
Journal of Critical Care
n3:obor
n5:FP
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
12
n3:projekt
n17:NS10014
n3:rokUplatneniVysledku
n4:2013
n3:svazekPeriodika
28
n3:tvurceVysledku
Stach, Zdeněk Vávrová, Jaroslava Oudemans-van Straaten, Heleen M. Tokarik, Monika Rusinová, Kateřina Jabor, Antonín Otáhal, Michal Leden, Pavel Polák, Ferdinand Hrubý, Jan Zakharchenko, Mykhaylo Balík, Martin
n3:wos
000312949700014
s:issn
0883-9441
s:numberOfPages
9
n18:doi
10.1016/j.jcrc.2012.06.003